News
InSyBio announces Novel of Multiple Taste Predictor based on a Multiobjective Machine Learning method
A novel predictor for multiple taste sensations based on a multi-objective Machine Learning method was published by InSyBio in the NPJ Science of Food journal of the Springer Nature publishing company (https://rdcu.be/dOVbA). This new predictor, namely Virtuous Multi-Taste, was developed in collaboration with a team of exceptional researchers from Politecnico di Torino (Italy), Industrial Systems… Continue reading→
InSyBio Harnesses the Power of Clinical Data developing AI tools for Cardiovascular Disease Treatment Optimization
Cardiovascular diseases (CVDs) are the leading cause of death globally, with 17.9 million annual deaths. InSyBio has partnered with Syndesis, the data and technology catalyst to a truly global, multi-continent network of healthcare and life sciences organizations, to address this enormous global health issue. We focused on two specific heart diseases, congestive heart failure (CHF)… Continue reading→
InSyBio Suite Version 3.2 is released including an integrated workflow and toolbox for single-cell RNA-sequencing analysis
Single-cell RNA sequencing is a powerful genomic method used to detect and analyze RNA molecules in biological samples at a single-cell level. It has proven successful in studying cell composition, proliferation, and migration. However, analyzing the data presents challenges due to standardization issues, data scarcity, and difficulties in integrating datasets with other sequencing technologies. The… Continue reading→
InSyBio recognized as the best Start-Up Initiative in 2023 at CPHI Pharma Awards
Barcelona, October 25th, 2023: CPHI Barcelona announced the winners of the prestigious 2023 CPHI Pharma Awards. The awards recognise outstanding achievements and contributions from the global pharma industry and supply chain across 12 wide-ranging categories. InSyBio won the best Start-Up Initiative in Pharma for 2023. CPHI is the biggest worldwide exhibition and event for the… Continue reading→
Syndesis Health and InSyBio Partner in Predictive Modelling and Biomarker Discovery
InSyBio, a leading biotechnology company that has developed a suite of advanced AI tools for biomarker discovery in clinical and multi-omics data, has announced a strategic partnership with Syndesis Health, a leader in global real-world evidence. The partnership aims to leverage the clinical and genomic data on Syntium, Syndesis’ data platform of global healthcare data, to accelerate… Continue reading→
InSyBio Suite Version 3.1 is released facilitating interactive and efficient network and machine-learning driven multi-omics data analysis
An increasing number of pharma and academic labs are getting access to multi-omics and multi-modal datasets. However, their processing requires multiple tools, while network analytics and data visualization can become challenging considering the high dimensionality, complexity and the presence of mutual information among different omics technologies. Moreover, predictive analytics using multi-omics data suffers from the… Continue reading→
Fitly Health & InSyBio have partnered to create the world’s first Metabolic AI™ precision nutrition program for metabolic syndrome, prediabetes, and Type 2 diabetes
Fitly Health has partnered with InSyBio to deliver life-changing outcomes for patients and employees with metabolic disorders who need to lose weight. Everyone has a unique metabolism and research now shows that our metabolic health is largely affected by diet-influenced changes to our gut microbiome. In other words, existing dietary interventions would be more effective in… Continue reading→
Understanding Taste by Studying the Protein-Protein Interactions of Taste Receptors
Understanding the underlined cellular mechanisms of human taste is an essential step for designing new food products and for improving the taste of food, nutraceutical, food supplements and even pharmaceutical products. Moreover, taste mechanisms have been evolutionary linked with protective mechanisms against hazardous compounds, thus understanding how taste works at a molecular level and its… Continue reading→
InSyBio enters Loyal VC investment Stage 2 and initiates the next financing round
In April 2023, InSyBio entered the second investment stage of the Loyal VC program and will receive follow-up funding from the Toronto, Canada-based international fund with active partnerships with Founder Institute and INSEAD. This funding will be part of InSyBio’s ongoing Series A financial round of a total of 2,000,000 Euros, with Loyal VC further assisting in… Continue reading→
InSyBio facilitates food design through an interpretable Umami taste predictor
InSyBio, through its participation in the Virtuous Project together with a prestigious team of researchers and industry players, has recently contributed to the implementation of the Virtuous Umami tool, a tool which can accurately predict the umami taste. This machine learning-based tool was tested against five databases related to foods or natural compounds and demonstrated… Continue reading→